These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

307 related items for PubMed ID: 21095452

  • 1. Impact of mammalian target of rapamycin inhibition on autosomal-dominant polycystic kidney disease.
    Wüthrich RP, Kistler AD, Serra AL.
    Transplant Proc; 2010 Nov; 42(9 Suppl):S44-6. PubMed ID: 21095452
    [Abstract] [Full Text] [Related]

  • 2. Mammalian target of rapamycin and autosomal dominant polycystic kidney disease.
    Wüthrich RP, Serra AL.
    Transplant Proc; 2009 Nov; 41(6 Suppl):S18-20. PubMed ID: 19651290
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).
    Wahl PR, Serra AL, Le Hir M, Molle KD, Hall MN, Wüthrich RP.
    Nephrol Dial Transplant; 2006 Mar; 21(3):598-604. PubMed ID: 16221708
    [Abstract] [Full Text] [Related]

  • 4. Everolimus in patients with autosomal dominant polycystic kidney disease.
    Walz G, Budde K, Mannaa M, Nürnberger J, Wanner C, Sommerer C, Kunzendorf U, Banas B, Hörl WH, Obermüller N, Arns W, Pavenstädt H, Gaedeke J, Büchert M, May C, Gschaidmeier H, Kramer S, Eckardt KU.
    N Engl J Med; 2010 Aug 26; 363(9):830-40. PubMed ID: 20581392
    [Abstract] [Full Text] [Related]

  • 5. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease.
    Serra AL, Poster D, Kistler AD, Krauer F, Raina S, Young J, Rentsch KM, Spanaus KS, Senn O, Kristanto P, Scheffel H, Weishaupt D, Wüthrich RP.
    N Engl J Med; 2010 Aug 26; 363(9):820-9. PubMed ID: 20581391
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Comparison of folate-conjugated rapamycin versus unconjugated rapamycin in an orthologous mouse model of polycystic kidney disease.
    Kipp KR, Kruger SL, Schimmel MF, Parker N, Shillingford JM, Leamon CP, Weimbs T.
    Am J Physiol Renal Physiol; 2018 Aug 01; 315(2):F395-F405. PubMed ID: 29717938
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of mTOR inhibitor therapy in patients with early-stage autosomal dominant polycystic kidney disease: a meta-analysis of randomized controlled trials.
    He Q, Lin C, Ji S, Chen J.
    Am J Med Sci; 2012 Dec 01; 344(6):491-7. PubMed ID: 22902868
    [Abstract] [Full Text] [Related]

  • 11. Sirolimus produced S-shaped effect on adult polycystic kidneys after 2-year treatment.
    Soliman A, Zamil S, Lotfy A, Ismail E.
    Transplant Proc; 2012 Dec 01; 44(10):2936-9. PubMed ID: 23195001
    [Abstract] [Full Text] [Related]

  • 12. Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease.
    Zafar I, Ravichandran K, Belibi FA, Doctor RB, Edelstein CL.
    Kidney Int; 2010 Oct 01; 78(8):754-61. PubMed ID: 20686448
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. mTOR inhibitors in polycystic kidney disease.
    Watnick T, Germino GG.
    N Engl J Med; 2010 Aug 26; 363(9):879-81. PubMed ID: 20581393
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Late conversion to mammalian target of rapamycin inhibitor/proliferation signal inhibitors in kidney transplant patients: clinical experience in the last 5 years.
    Sola E, Lopez V, Gutierrez C, Cabello M, Burgos D, Molina MG, Hernandez D.
    Transplant Proc; 2010 Oct 26; 42(8):2859-60. PubMed ID: 20970551
    [Abstract] [Full Text] [Related]

  • 18. A study of sirolimus and mTOR kinase inhibitor in a hypomorphic Pkd1 mouse model of autosomal dominant polycystic kidney disease.
    Holditch SJ, Brown CN, Atwood DJ, Lombardi AM, Nguyen KN, Toll HW, Hopp K, Edelstein CL.
    Am J Physiol Renal Physiol; 2019 Jul 01; 317(1):F187-F196. PubMed ID: 31042058
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.